ASCO: Bayer’s Novel Drug Boosts Survival in Rare GI Cancer

CHICAGO (MedPage Today) — The novel kinase inhibitor regorafenib substantially reduces relapse risk from treatment-refractory gastrointestinal stromal tumors (GIST), clinical trial results showed.

Post a Comment

Comments are closed.